Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

BACKGROUND: The incidence of malignant pleural mesothelioma (MPM) is associated with exposure to asbestos, and projections suggest that the yearly number of deaths in Western Europe due to MPM will increase until 2020. Despite progress in chemo- and in multimodality therapy, MPM remains a disease wi...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Belyanskaya, Larisa L, Marti, Thomas M, Hopkins-Donaldson, Sally, Kurtz, Stefanie, Felley-Bosco, Emanuela, Stahel, Rolf A
Format:	Artigo
Sprog:	Inglês
Udgivet:	BioMed Central 2007
Fag:	Research
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC2134932/ https://ncbi.nlm.nih.gov/pubmed/17953743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-6-66
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin

Lignende værker